1. Home
  2. CTMX vs BVS Comparison

CTMX vs BVS Comparison

Compare CTMX & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • BVS
  • Stock Information
  • Founded
  • CTMX 2008
  • BVS 2011
  • Country
  • CTMX United States
  • BVS United States
  • Employees
  • CTMX N/A
  • BVS N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • CTMX Health Care
  • BVS Health Care
  • Exchange
  • CTMX Nasdaq
  • BVS Nasdaq
  • Market Cap
  • CTMX 544.2M
  • BVS 448.8M
  • IPO Year
  • CTMX 2015
  • BVS 2021
  • Fundamental
  • Price
  • CTMX $3.32
  • BVS $6.64
  • Analyst Decision
  • CTMX Strong Buy
  • BVS Strong Buy
  • Analyst Count
  • CTMX 5
  • BVS 5
  • Target Price
  • CTMX $5.30
  • BVS $14.40
  • AVG Volume (30 Days)
  • CTMX 4.3M
  • BVS 294.3K
  • Earning Date
  • CTMX 11-06-2025
  • BVS 11-04-2025
  • Dividend Yield
  • CTMX N/A
  • BVS N/A
  • EPS Growth
  • CTMX 263.20
  • BVS N/A
  • EPS
  • CTMX 0.49
  • BVS 0.03
  • Revenue
  • CTMX $141,100,000.00
  • BVS $564,142,000.00
  • Revenue This Year
  • CTMX N/A
  • BVS N/A
  • Revenue Next Year
  • CTMX N/A
  • BVS $6.88
  • P/E Ratio
  • CTMX $6.80
  • BVS $240.50
  • Revenue Growth
  • CTMX 18.01
  • BVS 5.08
  • 52 Week Low
  • CTMX $0.40
  • BVS $5.81
  • 52 Week High
  • CTMX $3.49
  • BVS $14.38
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 75.86
  • BVS 42.20
  • Support Level
  • CTMX $3.11
  • BVS $6.46
  • Resistance Level
  • CTMX $3.39
  • BVS $7.14
  • Average True Range (ATR)
  • CTMX 0.24
  • BVS 0.26
  • MACD
  • CTMX 0.10
  • BVS -0.02
  • Stochastic Oscillator
  • CTMX 90.91
  • BVS 34.67

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Share on Social Networks: